SYNAGEVA BIOPHARMA CORP
DelistedCIK 911326fmd_07F0V0DQTRPSMSSFWT1NDN6GFNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Mar 31, 2015, 21 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 2 | 15 | 13 | 6 |
| Research and development | 7 | 10 | 17 | 37 | 80 | 143 |
| Selling, general and administrative | – | – | 9 | 17 | 28 | 54 |
| Total operating expenses | 10 | 14 | 27 | 58 | 109 | 199 |
| Operating income | (10) | (13) | (25) | (43) | (96) | (192) |
| Interest expense | 1 | – | 0 | – | – | – |
| Interest and investment income | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | 0 | 2 | (0) | – | 0 | (0) |
| Income before taxes | – | – | (25) | (43) | (95) | (192) |
| Income tax expense | – | – | – | – | 0 | 1 |
| Net income from continuing operations | – | – | – | – | (95) | (193) |
| Net income | (11) | (11) | (25) | (43) | (95) | (193) |